Tesamorelin

Overview

Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH) consisting of the full 44 amino acid GHRH sequence stabilized by a trans-3-hexenoic acid modification. It is FDA-approved under the brand name Egrifta for the treatment of excess abdominal fat in HIV-positive adults with lipodystrophy.

Mechanism of Action

Tesamorelin binds to and activates pituitary GHRH receptors, stimulating endogenous GH production and subsequent IGF-1 elevation. The resulting increase in GH drives lipolysis in visceral adipose tissue. The N-terminal modification extends its half-life compared to native GHRH while preserving full receptor binding.

Common Research Uses

• HIV-associated lipodystrophy research
• Visceral fat reduction studies
• GH axis research
• Metabolic and body composition research
• Cardiovascular risk factor studies

Vendors That Carry Tesamorelin